Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Mikhail V Ovanesov"'
Autor:
Wojciech Jankowski, Stepan S. Surov, Nancy E. Hernandez, Atul Rawal, Marcos Battistel, Daron Freedberg, Mikhail V. Ovanesov, Zuben E. Sauna
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic activity. However, DOAC treatment carries the risk of antico
Externí odkaz:
https://doaj.org/article/61c278e166c64672affea2a9f7d21b28
Autor:
Ivan D. Tarandovskiy, Stepan S. Surov, Leonid A. Parunov, Yideng Liang, Wojciech Jankowski, Zuben E. Sauna, Mikhail V. Ovanesov
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Thrombin generation (TG) and fibrin clot formation represent the central process of blood coagulation. Up to 95% of thrombin is considered to be generated after the clot is formed. However, this was not investigated in depth. In this study,
Externí odkaz:
https://doaj.org/article/dca2acebe37f4b8dbe886c06c41fd9bf
Publikováno v:
Thrombosis Journal, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Fluorogenic thrombin generation (TG) is a global hemostasis assay that provides an overall representation of hemostasis potential. However, the accurate detection of thrombin activity in plasma may be affected by artifacts inheren
Externí odkaz:
https://doaj.org/article/a8aca791941b4f26874d39baf9ca8f78
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 16, p 12920 (2023)
Preclinical evaluation of drugs in animals helps researchers to select potentially informative clinical laboratory markers for human trials. To assess the utility of animal thrombin generation (TG) assay, we studied the sensitivity of animal plasmas
Externí odkaz:
https://doaj.org/article/e16746b1151943d782d321b47ae4bd87
Autor:
William C. Chang, Joseph W. Jackson, Kellie R. Machlus, Alisa S. Wolberg, Mikhail V. Ovanesov
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 3, Pp 447-455 (2021)
Abstract Introduction The thrombin generation (TG) test is a global hemostasis assay sensitive to procoagulant conditions. However, some TG assays may underestimate elevated TG when the thrombin fluorogenic substrate is depleted or fluorescence is at
Externí odkaz:
https://doaj.org/article/935b161d5fba47678421fa79e99f597d
Autor:
Yideng Liang, Joseph W. Jackson, Samuel A. Woodle, Stepan S. Surov, Leonid A. Parunov, Dorothy E. Scott, Mark Weinstein, Timothy K. Lee, Mikhail V. Ovanesov
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 1, Pp 211-222 (2021)
Abstract Background Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis‐implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa
Externí odkaz:
https://doaj.org/article/ab2eec995bec476b91c3b022656c3222
Autor:
Wojciech Jankowski, Joseph McGill, H.A.Daniel Lagassé, Stepan Surov, Gary Bembridge, Campbell Bunce, Edward Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Khan, Joseph Marcotrigiano, Mikhail V. Ovanesov, Zuben E. Sauna
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2668-2678 (2019)
Abstract: Vatreptacog alfa (VA), a recombinant activated human factor VII (rFVIIa) variant with 3 amino acid substitutions, was developed to provide increased procoagulant activity in hemophilia patients with inhibitors to factor VIII or factor IX. I
Externí odkaz:
https://doaj.org/article/ef7a790689d44f5b9a7802adb877facf
Autor:
Svetlana A. Shestopal, Leonid A. Parunov, Philip Olivares, Haarin Chun, Mikhail V. Ovanesov, John R. Pettersson, Andrey G. Sarafanov
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 15, p 8134 (2022)
Single-chain variable fragments (scFv) are antigen-recognizing variable fragments of antibodies (FV) where both subunits (VL and VH) are connected via an artificial linker. One particular scFv, iKM33, directed against blood coagulation factor VIII (F
Externí odkaz:
https://doaj.org/article/026a20d758e149e5a1412c85d1c496da
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 5, Pp 944-945 (2020)
Externí odkaz:
https://doaj.org/article/b2f169bd185d433e85f9d7ad0aaab62e
Autor:
Leonid A Parunov, Yideng Liang, Qijin Lu, Alexey M Shibeko, Erik I. Tucker, Timothy K. Lee, Fazoil I Ataullakhanov, Dorothy Scott, Mikhail V Ovanesov
Publikováno v:
Blood Advances.
Inhibitors of coagulation factor (F) XIa are currently investigated as potential anticoagulant therapies. We hypothesized that circulating FXIa may be a potential target for these therapies. Using previous analyses of FXIa impurity in immune globulin